COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$960K

Filings

Firms Hired

Active Period

2015–2017

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2017	$230,000	7	2
2016	$380,000	4	1
2015	$350,000	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)	$960,000	11
THE OB-C GROUP, LLC	—	5

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	13
SENATE	13

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	10
Pharmacy	Pharmacy	6
Budget/Appropriations	Budget/Appropriations	2
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	1
Science/Technology	Science/Technology	1
Trade (domestic/foreign)	Trade (domestic/foreign)	1
Government Issues	Government Issues	1
Medicare/Medicaid	Medicare/Medicaid	1
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bills Explicitly Cited (24)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6114th Congress

21st Century Cures Act

2016 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $100,000 · Firm income: —

Matched citations: H.R. 6

S. 289114th Congress

American Cures Act

2016 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $100,000 · Firm income: —

Matched citations: S. 289

S. 3084114th Congress

American Innovation and Competitiveness Act

2016 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $100,000 · Firm income: —

Matched citations: S. 3084

H.R. 6114th Congress

21st Century Cures Act

2016 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 6

Show 20 more cited filings

S. 289114th Congress

American Cures Act

2016 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $80,000 · Firm income: —

Matched citations: S. 289

S. 3084114th Congress

American Innovation and Competitiveness Act

2016 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $80,000 · Firm income: —

Matched citations: S. 3084

H.R. 6114th Congress

21st Century Cures Act

2016 · second_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 6

S. 289114th Congress

American Cures Act

2016 · second_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $90,000 · Firm income: —

Matched citations: S. 289

S. 3084114th Congress

American Innovation and Competitiveness Act

2016 · second_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.

Client expense: $90,000 · Firm income: —

Matched citations: S. 3084

H.R. 6114th Congress

21st Century Cures Act

2016 · first_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Issues Related to Duchenne Muscular Dystrophy. Issues Related to Precision Medicine in Rare Diseases Discussions related to the role of Marathon Pharmaceuticals, LLC as a rare disease company and the sale of legacy products.

Client expense: $110,000 · Firm income: —

Matched citations: H.R. 6

S. 289114th Congress

American Cures Act

2016 · first_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Issues Related to Duchenne Muscular Dystrophy. Issues Related to Precision Medicine in Rare Diseases Discussions related to the role of Marathon Pharmaceuticals, LLC as a rare disease company and the sale of legacy products.

Client expense: $110,000 · Firm income: —

Matched citations: S. 289

H.R. 1537114th Congress

Advancing Hope Act of 2015

2015 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 1537

H.R. 2029114th Congress

Consolidated Appropriations Act, 2016

2015 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

HR 2029 - Consolidated Appropriations Act of 2016; provisions related to FDA product review.

Client expense: $90,000 · Firm income: —

Matched citations: HR 2029

H.R. 6114th Congress

21st Century Cures Act

2015 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 6

S. 1878114th Congress

Advancing Hope Act of 2016

2015 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $90,000 · Firm income: —

Matched citations: S. 1878

S. 289114th Congress

American Cures Act

2015 · fourth_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $90,000 · Firm income: —

Matched citations: S. 289

H.R. 1537114th Congress

Advancing Hope Act of 2015

2015 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 1537

H.R. 6114th Congress

21st Century Cures Act

2015 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 6

S. 1878114th Congress

Advancing Hope Act of 2016

2015 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $80,000 · Firm income: —

Matched citations: S. 1878

S. 289114th Congress

American Cures Act

2015 · third_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $80,000 · Firm income: —

Matched citations: S. 289

H.R. 1537114th Congress

Advancing Hope Act of 2015

2015 · second_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 1537

S. 289114th Congress

American Cures Act

2015 · second_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $50,000 · Firm income: —

Matched citations: S. 289

H.R. 1537114th Congress

Advancing Hope Act of 2015

2015 · first_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $130,000 · Firm income: —

Matched citations: H.R. 1537

S. 289114th Congress

American Cures Act

2015 · first_quarter · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)

Open original LDA filing ↗

Cited source text and reported amounts

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

Client expense: $130,000 · Firm income: —

Matched citations: S. 289

Source: Senate LDA

COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) — Lobbying Disclosure | Poliscope